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a b s t r a c t
Fabry disease is an X-linked recessive glycosphingolipid storage disorder caused by a deﬁciency of
lysosomal enzyme α-galactosidase A. It is recognized that Fabry disease patients often have ventricular
arrhythmias. Although the effectiveness of implantable cardioverter-deﬁbrillator (ICD) therapy in
patients with ventricular ﬁbrillation is established, there is little evidence regarding ICD therapy for
Fabry disease. Here, we report the case of patient with Fabry disease who was treated with an ICD and
presented with high deﬁbrillation thresholds.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Case report
We report the case of a 45-year-old man with a familial history
of Fabry disease. He had clinical manifestations from childhood
and was diagnosed with Fabry disease by an enzyme assay at 19
years of age. He began enzyme replacement therapy with agalsi-
dase alpha at age 34; however, by age 37, his kidney status
progressed to end-stage-renal disease requiring hemodialysis.
Technetium-99m-labelled methoxyisobutyl isonitrile myocardial
perfusion scintigraphy revealed no ischemic lesions at 43 years
of age.
He was transferred to our hospital due to cardiopulmonary
arrest at age 45. An electrocardiogram revealed ventricular ﬁbril-
lation, and sinus rhythm was restored by cardiac deﬁbrillation.
After intensive therapy, we planned an implantable cardioverter-
deﬁbrillator (ICD) implantation. He had normal vital signs
(blood pressure: 110/78 mmHg; heart rate: 75 bpm; O2 saturation:
97% on room air; and body temperature: 36.4 1C). Chest
X-ray revealed mild cardiomegaly and no pulmonary congestion.
The plasma brain natriuretic peptide level was 300.5 pg/mL. An
electrocardiogram during sinus rhythm showed signs of left
ventricle hypertrophy with a normal QRS duration (QRS duration:
124 ms; QTc: 0.435; S wave amplitude in leads V1þR wave
amplitude in leads V5¼4.92 mV). QTc was deﬁned as QT inter-
val/square root of RR interval. Transthoracic echocardiography
revealed left ventricular hypertrophy (interventricular septal
thickness at end-diastole 14.6 mm; left ventricular posterior wall
thickness at end-systole 15.0 mm; left ventricle mass 221 g) with a
preserved ejection fraction (left ventricular dimension at end-
diastole 39.1 mm; left ventricle dimension at end-systole
26.4 mm; ejection fraction 61.4%). Oral drug therapy included
carvedilol (2.5 mg/day), but no antiarrhythmic drugs were taken.
An ICD (FORTIFY ST VR; St. Jude Medical, St. Paul, MN, USA)
with a single-coil shock lead (DURATA 7122Q-52; St. Jude Medical,
St. Paul, MN, USA) was implanted in the right precordium because
he had an arteriovenous shunt for dialysis in his left forearm. The
deﬁbrillation thresholds (DFTs) were tested. He demonstrated high
DFTs (Fig. 1), which were deﬁned as safety margins of less than
10- J between the DFTs and the maximum energy output of the
implanted device [1]. The initial deﬁbrillation setting was as
follows: waveform, “Biphasic”; waveform mode, “Tilt”; shock
conﬁguration, “RV to Can”. Based on the patient's high DFTs, we
modiﬁed the device settings, changing the waveform mode to
Pulse Width, but the DFTs did not improve. We then extracted the
generator and the lead, and, although the patient had a shunt in
his left forearm, we moved the generator to the left precordium
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and replaced the single-coil shock lead with a dual-coil shock lead
(DURATA 7120Q-58; St. Jude Medical, St. Paul, MN, USA) in order
to improve the DFTs. Finally, after these changes, we achieved an
adequate DFT.
2. Discussion
To the best of our knowledge, this is the ﬁrst report of a patient
with Fabry disease presenting with high DFTs.
Predicting high DFTs in patients for whom ICD implantation is
planned is important; however, the association between Fabry
disease and high DFTs has not been systematically studied.
Rhythm and conduction abnormalities have been reported to exist
in Fabry disease as a result of the glycosphingolipid storage in
cardiomyocytes, conduction system cells, and endothelial cells [2].
As left ventricular hypertrophy is the most common manifestation
of Fabry disease, the high DFTs observed in this patient may be
attributable to myocardial hypertrophy, which is a well-known
substrate of high DFTs [3].
By managing the device settings and using a dual-coil lead, it
was possible to implant an ICD with an adequate deﬁbrillation
safety margin in this patient with high DFTs. Patients undergoing
right-sided ICD implantations have higher DFTs compared with
left-sided implants [4].
In the case presented here, a man with Fabry disease and
ventricular ﬁbrillation had high DFTs after ICD implantation.
Further reports should be accumulated in order to determine
whether Fabry disease is generally complicated with high DFTs.
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Fig. 1. Deﬁbrillation threshold (DFT) testing; the implantable cardioverter-deﬁbrillator (ICD) failed to terminate ventricular ﬁbrillation (intracardiac 20 J – failure;
intracardiac 30 J – failure; intracardiac 40 J – failure; and external 270 J – success).
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